LPAR5 and melanoma: In addition to our finding that PCa patients in the high LPAR5 expression group had worse survival, other LPAR subtypes were associated with poor survival such as LPAR1 in melanoma, LPAR2 in adrenocortical carcinoma, LPAR3 in pancreatic cancer, and LPAR4 in renal papillary carcinoma (Supplementary Fig. S6B).